JGH:止血粉TC-325治疗恶性肿瘤相关上消化道出血的疗效分析

2021-12-16 MedSci原创 MedSci原创

消化道出血是临床常见症候群,可由多种疾病所致。消化道是指从食管到肛门的管道,包括食管、胃、十二指肠、空肠、回肠、盲肠、结肠及直肠。

      肿瘤相关的上消化道 (UGI) 出血占所有UGI出血的5%,它可以以多种方式出现,从慢性低容量出血到急性血流动力学受损,肿瘤局部浸润会导致血管损伤后发生出血。内窥镜是一线治疗,然而这样的治疗方式的止血率低至40%,再出血率高达 30%。最重要的是,这些干预措施通常会降低对这些患者的生活质量和对长期结果产生重大影响。除此之外,栓塞、放疗和手术都可以为这些患者提供更明确的治疗效果。然而,在急性 UGI 出血的情况下,手术与较高的发病率和死亡率相关。TC-325是一种基于矿物质的止血粉末。它由一种无机和可吸收粉末组成,喷洒在流血的肿瘤表面,形成粘附和稳定的屏障,实现止血。因此,本项研究旨在评估TC-325治疗后的即时止血率。次要结果包括30天再出血率、输血需求变化以及治疗后7天和30天死亡率。

 

      研究人员前瞻性地收集了来自欧洲17个医疗中心的TC-325的使用数据。TC-325的使用方法是在急诊内窥镜检查期间,根据内窥镜医师的判断,针对肿瘤继发的上消化道出血使用喷血剂TC-325或标准止血技术的双重疗法或抢救疗法。

 

      本项研究共招募了105名继发于肿瘤破损的上消化道出血患者。基线时的 Blatchford 得分中位数为 10(四分位距 [IQR],7-12)。Rockall 得分中位数为 8(IQR,7-9)。102/105 (97%) 患者接受了TC-325的立即止血,15%的患者在30天内再次出血,20%的患者在30天内死亡。 比较治疗前后 3 周的输血单位数,治疗后输血需求有显着改善(P < 0.001)。每名患者平均减少一个单位。

 

      本项研究证实TC-325止血粉实现了很高的消化道即刻止血率,但是治疗肿瘤相关的上消化道出血后的再出血率相当,但是TC-325的使用有助于改善这些患者的输血需求。

 

 

原始出处:

Mohamed Hussein. Et al. Hemostatic powder TC-325 treatment of malignancy-related upper gastrointestinal bleeds: International registry outcomes. Journal of Gastroenterology and Hepatology.2021.

评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1723114, encodeId=b77d1e23114b0, content=<a href='/topic/show?id=0cc01998259' target=_blank style='color:#2F92EE;'>#上消化道#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19982, encryptionId=0cc01998259, topicName=上消化道)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b81833366357, createdName=zchen, createdTime=Wed Oct 19 18:36:10 CST 2022, time=2022-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1647332, encodeId=a40b164e332af, content=<a href='/topic/show?id=e9bae04003f' target=_blank style='color:#2F92EE;'>#疗效分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70400, encryptionId=e9bae04003f, topicName=疗效分析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=219323401160, createdName=rebeccajiejie, createdTime=Wed Aug 17 02:36:10 CST 2022, time=2022-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1654792, encodeId=22381654e92f3, content=<a href='/topic/show?id=62d163180de' target=_blank style='color:#2F92EE;'>#止血粉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63180, encryptionId=62d163180de, topicName=止血粉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6d0124562747, createdName=surilei, createdTime=Tue Apr 19 15:36:10 CST 2022, time=2022-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1263104, encodeId=8e91126310471, content=<a href='/topic/show?id=ebb5631e076' target=_blank style='color:#2F92EE;'>#止血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63170, encryptionId=ebb5631e076, topicName=止血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Sat Dec 18 10:36:10 CST 2021, time=2021-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1464710, encodeId=30eb1464e104d, content=<a href='/topic/show?id=32e765e6591' target=_blank style='color:#2F92EE;'>#消化道#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65765, encryptionId=32e765e6591, topicName=消化道)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b6e6676048, createdName=changhe715, createdTime=Sat Dec 18 10:36:10 CST 2021, time=2021-12-18, status=1, ipAttribution=)]
    2022-10-19 zchen
  2. [GetPortalCommentsPageByObjectIdResponse(id=1723114, encodeId=b77d1e23114b0, content=<a href='/topic/show?id=0cc01998259' target=_blank style='color:#2F92EE;'>#上消化道#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19982, encryptionId=0cc01998259, topicName=上消化道)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b81833366357, createdName=zchen, createdTime=Wed Oct 19 18:36:10 CST 2022, time=2022-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1647332, encodeId=a40b164e332af, content=<a href='/topic/show?id=e9bae04003f' target=_blank style='color:#2F92EE;'>#疗效分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70400, encryptionId=e9bae04003f, topicName=疗效分析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=219323401160, createdName=rebeccajiejie, createdTime=Wed Aug 17 02:36:10 CST 2022, time=2022-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1654792, encodeId=22381654e92f3, content=<a href='/topic/show?id=62d163180de' target=_blank style='color:#2F92EE;'>#止血粉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63180, encryptionId=62d163180de, topicName=止血粉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6d0124562747, createdName=surilei, createdTime=Tue Apr 19 15:36:10 CST 2022, time=2022-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1263104, encodeId=8e91126310471, content=<a href='/topic/show?id=ebb5631e076' target=_blank style='color:#2F92EE;'>#止血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63170, encryptionId=ebb5631e076, topicName=止血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Sat Dec 18 10:36:10 CST 2021, time=2021-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1464710, encodeId=30eb1464e104d, content=<a href='/topic/show?id=32e765e6591' target=_blank style='color:#2F92EE;'>#消化道#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65765, encryptionId=32e765e6591, topicName=消化道)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b6e6676048, createdName=changhe715, createdTime=Sat Dec 18 10:36:10 CST 2021, time=2021-12-18, status=1, ipAttribution=)]
    2022-08-17 rebeccajiejie
  3. [GetPortalCommentsPageByObjectIdResponse(id=1723114, encodeId=b77d1e23114b0, content=<a href='/topic/show?id=0cc01998259' target=_blank style='color:#2F92EE;'>#上消化道#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19982, encryptionId=0cc01998259, topicName=上消化道)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b81833366357, createdName=zchen, createdTime=Wed Oct 19 18:36:10 CST 2022, time=2022-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1647332, encodeId=a40b164e332af, content=<a href='/topic/show?id=e9bae04003f' target=_blank style='color:#2F92EE;'>#疗效分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70400, encryptionId=e9bae04003f, topicName=疗效分析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=219323401160, createdName=rebeccajiejie, createdTime=Wed Aug 17 02:36:10 CST 2022, time=2022-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1654792, encodeId=22381654e92f3, content=<a href='/topic/show?id=62d163180de' target=_blank style='color:#2F92EE;'>#止血粉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63180, encryptionId=62d163180de, topicName=止血粉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6d0124562747, createdName=surilei, createdTime=Tue Apr 19 15:36:10 CST 2022, time=2022-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1263104, encodeId=8e91126310471, content=<a href='/topic/show?id=ebb5631e076' target=_blank style='color:#2F92EE;'>#止血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63170, encryptionId=ebb5631e076, topicName=止血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Sat Dec 18 10:36:10 CST 2021, time=2021-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1464710, encodeId=30eb1464e104d, content=<a href='/topic/show?id=32e765e6591' target=_blank style='color:#2F92EE;'>#消化道#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65765, encryptionId=32e765e6591, topicName=消化道)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b6e6676048, createdName=changhe715, createdTime=Sat Dec 18 10:36:10 CST 2021, time=2021-12-18, status=1, ipAttribution=)]
    2022-04-19 surilei
  4. [GetPortalCommentsPageByObjectIdResponse(id=1723114, encodeId=b77d1e23114b0, content=<a href='/topic/show?id=0cc01998259' target=_blank style='color:#2F92EE;'>#上消化道#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19982, encryptionId=0cc01998259, topicName=上消化道)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b81833366357, createdName=zchen, createdTime=Wed Oct 19 18:36:10 CST 2022, time=2022-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1647332, encodeId=a40b164e332af, content=<a href='/topic/show?id=e9bae04003f' target=_blank style='color:#2F92EE;'>#疗效分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70400, encryptionId=e9bae04003f, topicName=疗效分析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=219323401160, createdName=rebeccajiejie, createdTime=Wed Aug 17 02:36:10 CST 2022, time=2022-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1654792, encodeId=22381654e92f3, content=<a href='/topic/show?id=62d163180de' target=_blank style='color:#2F92EE;'>#止血粉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63180, encryptionId=62d163180de, topicName=止血粉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6d0124562747, createdName=surilei, createdTime=Tue Apr 19 15:36:10 CST 2022, time=2022-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1263104, encodeId=8e91126310471, content=<a href='/topic/show?id=ebb5631e076' target=_blank style='color:#2F92EE;'>#止血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63170, encryptionId=ebb5631e076, topicName=止血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Sat Dec 18 10:36:10 CST 2021, time=2021-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1464710, encodeId=30eb1464e104d, content=<a href='/topic/show?id=32e765e6591' target=_blank style='color:#2F92EE;'>#消化道#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65765, encryptionId=32e765e6591, topicName=消化道)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b6e6676048, createdName=changhe715, createdTime=Sat Dec 18 10:36:10 CST 2021, time=2021-12-18, status=1, ipAttribution=)]
    2021-12-18 智慧医人

    #止血#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1723114, encodeId=b77d1e23114b0, content=<a href='/topic/show?id=0cc01998259' target=_blank style='color:#2F92EE;'>#上消化道#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19982, encryptionId=0cc01998259, topicName=上消化道)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b81833366357, createdName=zchen, createdTime=Wed Oct 19 18:36:10 CST 2022, time=2022-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1647332, encodeId=a40b164e332af, content=<a href='/topic/show?id=e9bae04003f' target=_blank style='color:#2F92EE;'>#疗效分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70400, encryptionId=e9bae04003f, topicName=疗效分析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=219323401160, createdName=rebeccajiejie, createdTime=Wed Aug 17 02:36:10 CST 2022, time=2022-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1654792, encodeId=22381654e92f3, content=<a href='/topic/show?id=62d163180de' target=_blank style='color:#2F92EE;'>#止血粉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63180, encryptionId=62d163180de, topicName=止血粉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6d0124562747, createdName=surilei, createdTime=Tue Apr 19 15:36:10 CST 2022, time=2022-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1263104, encodeId=8e91126310471, content=<a href='/topic/show?id=ebb5631e076' target=_blank style='color:#2F92EE;'>#止血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63170, encryptionId=ebb5631e076, topicName=止血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Sat Dec 18 10:36:10 CST 2021, time=2021-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1464710, encodeId=30eb1464e104d, content=<a href='/topic/show?id=32e765e6591' target=_blank style='color:#2F92EE;'>#消化道#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65765, encryptionId=32e765e6591, topicName=消化道)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b6e6676048, createdName=changhe715, createdTime=Sat Dec 18 10:36:10 CST 2021, time=2021-12-18, status=1, ipAttribution=)]
    2021-12-18 changhe715

    #消化道#

    0

相关威廉亚洲官网

Invivoscribe宣布在欧盟进行关键报批,拓展在华布局和活动

面向血液系统恶性肿瘤开发诊断产品和试剂并进行商业化的行业先驱Invivoscribe, Inc.今天宣布在欧盟进行一项关键报批,并拓展在华布局和活动。

吴洲鹏:恶性肿瘤患者静脉血栓栓塞症VTE复发的防治

恶性肿瘤是VTE复发的重要风险因素。传统抗凝疗法患者依从性差、抗凝剂量不足,显著增加VTE复发的风险。VTE长期抗凝需要权衡疗效、安全性及患者依从性,利伐沙班更具优势。

我国增加12个病种纳入儿童血液病恶性肿瘤救治管理病种范围

3月16日,国家卫健委发布《关于进一步扩大儿童血液病恶性肿瘤救治管理病种范围的通知》(以下简称《通知》),宣布将12个病种纳入儿童血液病恶性肿瘤救治管理病种范围。

卫健委:中国恶性肿瘤的5年生存率提高近10%

某些恶性肿瘤比如食管癌,五年生存率已经高于美国等发达国家。

Clin Cancer Res:三特异性T细胞激活蛋白HPN536在表达间皮素的恶性肿瘤中的活性

间皮素(Mesothelin,MSLN)是一种糖磷脂酰肌醇(GPI)连接的肿瘤抗原,在多种恶性肿瘤中过表达,包括卵巢癌、胰腺癌、肺癌和三阴性乳腺癌。

Clin Cancer Res:DNA甲基转移酶抑制剂Guadecitabine联合顺铂和吉西他滨治疗实体恶性肿瘤

DNA甲基转移酶抑制剂Guadecitabine联合顺铂和吉西他滨治疗实体恶性肿瘤的推荐2期剂量